Can melatonin be used to treat insomnia in adult patients receiving active cancer therapy?

Melatonin Should NOT Be Used as First-Line Treatment for Insomnia in Cancer Patients

The American Academy of Sleep Medicine (AASM) explicitly recommends against using melatonin for treatment of sleep onset or sleep maintenance insomnia in adults, and this applies to cancer patients as well. 1

Guideline-Based Recommendations

The most authoritative guidance comes from the 2017 AASM Clinical Practice Guideline, which states: "We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults." This is based on insufficient evidence of efficacy for chronic insomnia 1.

For cancer patients specifically, the 2014 Annals of Oncology systematic review on sleep disturbance in adults with cancer reinforces this position. The guideline explicitly states that over-the-counter herbal substances including melatonin were NOT recommended for treatment of chronic insomnia due to relative lack of efficacy and safety data, plus potential for rebound insomnia 2. The Alberta Medical Association concluded that the efficacy of melatonin is inconclusive, and they did not recommend over-the-counter products as sleep aids 2.

The Evidence Paradox

Here's where clinical judgment becomes critical: While guidelines recommend against melatonin, recent research studies (2026) show contradictory positive results:

• A 2026 prospective comparative trial found melatonin 3 mg/day showed statistically significant superiority over olanzapine in sleep quality scores with a more favorable adverse effect profile 3
• Another 2026 trial in breast cancer patients showed significant improvements in sleep latency, sleep efficiency, and overall sleep quality with 6 mg/day melatonin 4
• A 2016 randomized controlled trial demonstrated 46.53% improvement in insomnia with melatonin versus 11.30% with placebo 5

However, a 2025 Cochrane systematic review (the highest quality evidence synthesis) concluded: "The available evidence is of very low certainty, so we are unable to draw conclusions about the effects of melatonin on quality of life and sleep at three months in people receiving treatment for cancer" 6.

Clinical Decision Algorithm

Given the conflicting evidence, here is the recommended approach:

1. First-line: Cognitive Behavioral Therapy for Insomnia (CBT-I) - This is the standard of care with the most favorable benefit-to-risk ratio 2, 1

2. If CBT-I is unavailable or ineffective, consider FDA-approved pharmacotherapy:

   • Short-acting benzodiazepine receptor agonists (zaleplon, zolpidem) for sleep onset 1
   • Eszopiclone for sleep onset and maintenance 1
   • Doxepin (3-6 mg) for sleep maintenance 1
   • Suvorexant for sleep maintenance 1

3. Melatonin may be considered as an adjunct or alternative ONLY when:

   • Standard pharmacotherapy is contraindicated or causes intolerable side effects
   • Patient strongly prefers a "natural" option and understands the limited evidence
   • Used at 3-6 mg doses taken 2 hours before bedtime
   • Limited to short-term use (2-4 weeks) with reassessment

Critical Caveats

Important safety considerations in cancer patients:

• Antihistamines (diphenhydramine) should be avoided due to daytime sedation and delirium risk, especially in older patients and those with advanced cancer 2
• Long-acting benzodiazepines should be avoided due to accumulation and impaired clearance 2
• Always consider drug-drug interactions with chemotherapy and other cancer treatments 2
• Address underlying causes first: pain, medication side effects, anxiety, depression 2

The evidence quality problem: Most melatonin studies in cancer patients have small sample sizes, short duration, and methodological limitations. The 2025 Cochrane review rated the evidence as "very low certainty" due to high risk of bias and insufficient data 6.

Bottom Line

While emerging research suggests potential benefit, current clinical practice guidelines do not support melatonin as a recommended treatment for insomnia in cancer patients. If used, it should be considered an off-guideline option after standard treatments have been exhausted or are inappropriate, with informed patient consent about the limited evidence base. The decision must weigh the low risk profile of melatonin against its unproven efficacy compared to FDA-approved alternatives that have stronger evidence for improving sleep-related morbidity and quality of life.